UPDATE (6/21/26): Chris Smith’s Tour Divide journey has come to an end, but the adventure and the inspiration continues.

After pushing through one of the toughest self-supported races in the world, Chris made the decision to step away from the ride. While the finish line wasn’t reached this time, we couldn’t be prouder of Chris for taking on the challenge and reminding us that adventure is about so much more than the outcome.

At Waypoint, we believe it’s not always about finishing it’s about showing up, taking the leap, and discovering what’s possible.

Thank you for cheering Chris on. We hope you’ll continue to follow his next adventure and support the mission that makes these life-changing experiences possible for people with disabilities.
_____________________

This June, Chris Smith — Waypoint Adventure board member and passionate mountain biker — will attempt to become the first para-athlete to complete the 2,700-mile Tour Divide, one of the toughest self-supported races on the planet.

As part of this personal challenge, Chris, who was declared legally blind due to Stargardt Disease, is raising funds on behalf of Waypoint Adventure to support the organization’s mission of expanding access to outdoor adventure programs for people with disabilities. All contributions made through this campaign will be directed to Waypoint Adventure and used to support its programs and participants.

You can power this historic ride! Sponsor a mile for $100 (or give $25/week) and be part of every push, climb, and coast.

Your impact goes beyond the trail. $20 funds one person’s participation in Waypoint Adventure programs, and $100 supports five individuals in building confidence, independence, and community through outdoor adventure.

Give a mile. Open the outdoors. Redefine what’s possible!

Generously Sponsored by:

Special thanks to Alkeus Pharmaceuticals for supporting Chris's Tour Divide ride. Based in Cambridge, Massachusetts, Alkeus is a biopharmaceutical company dedicated to preserving sight and developing innovative treatments for retinal diseases, including Stargardt disease—the condition Chris was diagnosed with in 2009. Learn more about their groundbreaking work at Alkeus Pharmaceuticals, Inc.